Combines Sail’s patented eRNA™ and targeted nanoparticle modality with Johnson & Johnson’s world-class development, manufacturing, and commercialization capabilities to create scalable and potentially curative In Vivo CAR-T therapies for immune-mediated diseases Sail to receive initial payments of $785 million from Johnson & Johnson1, including a $465 million equity investment2 and additional milestone payments of $140 million subject to achievement of certain development mil